1. Pink Sheet
  2. >>Geography
  3. >>Europe

‘We Tried It, It Does Not Work’ – The Problems With The EU’s SPC Manufacturing Waiver

Industry Leaders Outline Difficulties With Mechanism At European Legal Affairs Conference

 
• By Dave Wallace

While the European supplementary protection certificate manufacturing waiver was once seen as a triumph for the region’s off-patent industry, concerns are now being raised over how the mechanism is implemented. Attendees at Medicines for Europe’s legal affairs conference in Dublin last week heard the latest.

Medicines for Europe Legal Affairs Conference Panel
A legal affairs conference panel discussed the SPC manufacturing waiver • Source: Medicines for Europe

Back in June 2019, the European generics and biosimilars industry was celebrating the imminent arrival of the supplementary protection certificate (SPC) manufacturing waiver. The mechanism had been long-sought by the off-patent industry, and promised to allow European manufacturers to compete on an equal footing with non-EU competitors by permitting manufacturing for export outside the EU, as well as stockpiling for day-one launch within the EU, during the term of SPCs (see sidebar).

Five years on, however, it is clear that many are not happy with how the SPC manufacturing waiver functions in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

England’s NHS Plan Eyes Cancer Vaccine Boost, Single Formulary & ‘Pay For Impact’ Drug Deal

 
• By Eliza Slawther

The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By Vibha Sharma

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

Industry Groups Back EU Life Sciences Strategy As Commission Pledges Clinical Trial Investment

 
• By Eliza Slawther

Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.

Lawyers Weigh In On ‘Sunshine’ Clause In EU Pharma Reform Package

 
• By Eliza Slawther

The Council of the EU has not taken forward a proposal from the European Parliament that would require companies to disclose the transfers of value they make to health care professionals and health care organizations – lawyers weigh in on the diverging proposals.

More from Generics Bulletin

CivicaScript Offers Generic Tecfidera To US Pharmacies For $47 Per Bottle

 
• By Urtė Fultinavičiūtė

As CivicaScript continues its mission to make treatments more accessible with its newly launched generic Tecfidera at a low price, generic drug coverage remains under threat, showed AAM analysis.

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By Dave Wallace

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment.